Introduction {#s1}
============

Prostate and rectal cancers account for the most common pelvic malignancies in the male population and can present either synchronously or metachronously \[[@R01]\]. Without a doubt, prostate and rectal cancers are more likely to present metachronously, with prior radiotherapy for prostate cancer being the main proposed link \[[@R02]\]. Despite the significant advances in radiotherapy administration techniques, it is believed, although still of clinical controversy, that previous external beam radiotherapy for prostate cancer predisposes to the development of rectal cancer, as the rectum, most specifically the anterior rectum, receives a dose of the radiotherapy beam \[[@R03], [@R04]\]. The relevant interaction is more blur when it comes to prostate brachytherapy \[[@R05], [@R06]\]; however, it must be mentioned that the conflicting findings regarding the impact of prostate radiotherapy in future rectal cancer development could be explained by the fact that the mutagenic effects of radiotherapy are accumulative in nature and therefore studies with long-term follow-up are needed to establish any possible associations.

As the majority of men will develop at some age prostate neoplasias and taking into account the high prevalence of rectal cancer, despite the implementation of screening protocols and the advances in terms of primary prevention for both of these malignancies, it would be not endangered to claim that the scenario of synchronous prostate and rectal cancer will be increasingly frequent. Moreover, considering the anatomic proximity of the prostate and the rectum, which enables a locally advanced cancer to invade in tissue continuity the other, it is evident that the accurate diagnostic work-up and treatment strategy requires a multidisciplinary approach, in order to optimize the standards of the care delivered and maintain the patient's quality of life. Herein, our aim is to provide a comprehensive review of the published literature regarding the management of the, not as infrequent as believed to be, challenging scenario of synchronous prostate and rectal cancer in a framework of a patient-centered multidisciplinary approach.

Methods {#s2}
=======

We performed a comprehensive review of the published literature in PubMed database, using "prostate cancer", "rectal cancer", "synchronous", "simultaneous" and their combinations as key phrases. Studies published in other than the English language were not included in our review. The review of the literature was performed independently by two of the contributing authors (CS and NL).

Results {#s3}
=======

Our literature search yielded eight papers which were suitable to the purpose of our review \[[@R07]\]; three were case reports and the remaining five referred to case series, describing a total of 23 cases with synchronous prostate and rectal cancers. In a general overview, the vast majority of patients presented with symptoms suggestive of a colorectal lesion and in the sequential diagnostic work-up, the suspicion of a concurrent prostate malignancy occurred as a result of an abnormal digital rectal examination or elevated PSA titer, fact which led to further imaging of the pelvis and if appropriate the performance of biopsies of the prostate gland. However, in one of the included studies \[[@R12]\], the authors performed a prospective screening assessment for prostate cancer in a group of 20 patients who were scheduled to undergo an abdominoperineal resection for rectal cancer, detecting a rectal cancerous lesion in three out of the 20 cases.

In terms of the most preferred surgical intervention with curative intent, 8/23 patients underwent radical retropubic prostatectomy and abdominoperineal excision or low anterior resection depending on the tumor location, while 2/23 were submitted to pelvic exenteration with formation of ileal or colonic conduit respectively. Another option adopted was the utilization of chemoradiotherapy with or without androgen deprivation therapy aiming to achieve maximal regression primarily of the prostate cancer, followed by either low anterior or abdominoperineal resection for the remaining rectal tumor (4/23 cases).

The patients' demographics, presenting features, histological characteristics of the prostate and rectal cancers, as well as the treatment strategies followed on each occasion and the outcome of the interventions were retrieved and are presented in a detailed manner in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### Presentation of Patients' Demographics, Presenting Features, Histological Characteristics of the Prostate and Rectal Cancers, as Well as the Treatment Strategies Followed on Each Occasion and the Outcome of the Interventions

  Authors                  Age   Presenting feature(s)                                                                                    Prostate cancer features                                                   Rectal cancer features                                                 Treatment                                                                                        Postoperative complications                            Outcome
  ------------------------ ----- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------
  Klee et al \[[@R07]\]    52    PSA 9.1 ng/mL                                                                                            Gleason grade 7/10, stage T2C prostate adenocarcinoma right lateral wall   4 cm Duke's stage B, moderately differentiated rectal adenocarcinoma   APR + radical rertropubic prostatectomy/blood loss 1,200 mL/operating time 4 h                   Bowel obstruction and ischemic colostomy/LOS 16 days   At a minimum of 1 year of follow-up, all three patients had an undetectable PSA, and the rectal cancers remained in remission.
  Klee et al \[[@R07]\]    70    PSA 5.9 ng/mL on routine rectal examination benign prostate, a left posterior lateral rectal wall mass   Gleason grade 6/10, stage T2A prostatic adenocarcinoma in right apex       2 cm Duke's stage A, moderately differentiated rectal adenocarcinoma   APR + radical retropubic prostatectomy/blood loss 700 mL/operating time 3 h                      Nil reported/LOS 8 days                                
  Klee et al \[[@R07]\]    64    PSA 6.1 ng/mL, change of bowel habits, induration in left prostate base and PR bleeding in DRE           Gleason grade 7/10 adenocarcinoma in left side and in the right base       4.5 cm non-invasive villous adenoma without cancerous features         LAR + radical retropubic prostatectomy/blood loss 1,100 mL/operating time 2.25 h                 Rectal and bladder neck stricture/LOS 6 days           
  Siu et al \[[@R08]\]     72    PSA 9 ng/mL                                                                                              Gleason grade 6/10 prostate cancer                                         Not reported                                                           Radiotherapy                                                                                     Non applicable                                         In 2-year follow-up colonoscopy revealed no recurrence and PSA level was 0.7 ng/mL.
  Siu et al \[[@R08]\]     73    Rectal tumor detected by DRE, PSA 7.9 ng/mL                                                              Gleason grade 7/10 adenocarcinoma                                          3 cm T3 rectal cancer at dentate line                                  5-FU and radiotherapy                                                                            Non applicable                                         In 1-year follow-up no evidence of residual or recurrent rectal malignancy, PSA level 0.5 ng/mL.
  Lin et al \[[@R09]\]     68    Rectal bleeding-rectal mass at DRE, PSA 57 ng/mL                                                         T2N2M0 prostate adenocarcinoma (Gleason grade 5 (3 + 2))                   3 cm T4N0M0 (Dukes' stage C) rectal adenocarcinoma                     LAR + radical retropubic prostatectomy + FOLFOX4, switched to FORFILI and then to capecitabine   Not reported                                           Death due to recurrence 47 months postoperatively
  Lin et al \[[@R09]\]     65    Rectal bleeding-rectal mass at DRE, PSA 27 ng/mL                                                         T3N0M0 prostate adenocarcinoma (Gleason grade 4 (2 + 2))                   3 cm T4N1M0 (Dukes' stage C) rectal adenocarcinoma                     LAR + radical retropubic prostatectomy + FOLFOX4                                                 Not reported                                           In 20-month follow-up asymptomatic
  Lin et al \[[@R09]\]     70    Rectal bleeding-rectal mass at DRE, PSA 65 ng/mL                                                         T3N1M0 prostate adenocarcinoma (Gleason grade 5 (2 + 3))                   T3N0M0 (Dukes' stage B) rectal adeno­carcinoma                         APR + radical retropubic prostatectomy + FOLFOX4                                                 Not reported                                           In 24-month follow-up asymptomatic
  Ayhan et al \[[@R10]\]   84    Hematemesis and rectal mass detected by DRE                                                              T2N0M0 prostate adenocarcinoma                                             T3N1M1 rectal adenocarcinoma                                           APR                                                                                              Pulmonary edema + respiratory infection                Died immediate post-operative period

Abbreviations: PSA: prostate specific antigen; DRE: digital rectal examination; APR: abdominoperineal resection; LAR: low anterior resection; LOS: length of stay.

###### Presentation of Patients' Demographics, Presenting Features, Histological Characteristics of the Prostate and Rectal Cancers, as Well as the Treatment Strategies Followed on Each Occasion and the Outcome of the Interventions

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                     Age                                            Presenting feature(s)                                                                                                                                                                               Prostate cancer features                                Rectal cancer features                                                                                 Treatment                                                                                                                    Postoperative complications                                                                   Outcome
  --------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ozsoy et al \[[@R11]\]      68                                             PSA 10 ng/mL                                                                                                                                                                                        cT3aN0M0/Gleason grade 8                                pT3N0 rectal adenocarcinoma                                                                            Radiotherapy                                                                                                                 Non-applicable                                                                                Dead due to liver metastases from rectal primary/no evidence of prostate cancer recurrence at 1.08 years follow-up

  Kavanagh et al \[[@R12]\]   n = 9 patients (mean age: 67.8 ± 10.3 years)   Rectal bleeding (n = 5), partial obstruction (n = 1), tenesmus (n = 1) and incidental during imaging for prostate cancer (n = 2)/elevated PSA in seven cases (mean PSA values: 21.4 ± 15.2 ng/mL)   Not reported                                            In group with no distant metastases (n = 5): ypT3N0, ypT4N1, ypT3N0, ypT3N1 (not reported for n = 1)   In group with no distant metastases (n = 5):\                                                                                Wound infection (n = 2), foot drop + intra-abdominal collection (n = 1)/LOS: 33 ± 25.4 days   In group with no distant metastases (n = 5): dead with no evidence of recurrence after 10 years (n = 1), dead due to metastases after 29 months (n = 1), alive at 7 months with no evidence of recurrence (n = 1), alive at 4 years with metastases, alive at 3 months with no evidence of recurrence (n = 1)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                1) Radiotherapy + APR + prostatectomy (n = 1)\                                                                                                                                                                             In group with distant metastases (n = 4): mean survival 8.5 months (range: 1 - 14 months)
                                                                                                                                                                                                                                                                                                                                                                                                                                                2) Radiotherapy + pelvic exenteration + ileal conduit (n = 1)\                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                3) Radiotherapy + pelvic exenteration + colonic conduit (n = 1)\                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                4) Radiotherapy + watchful waiting (n = 1)\                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                5) Prostatectomy + CRT + LAR (n = 1)\                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                In group with distant metastases (n = 4):\                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                1) Hormonal therapy + chemotherapy\                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                2) Hormonal therapy + anterior resection\                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                3) Hormonal therapy + palliation\                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                4) watchful waiting/spinal decompression and radiotherapy                                                                                                                                                                  

  Terris et al \[[@R13]\]     68                                             Not reported regarding rectal cancer/PSA 8.2 ng/mL                                                                                                                                                  Stage T1c, Gleason grade 3 + 3 prostate cancer          Not reported                                                                                           Preoperative radiotherapy + APR                                                                                              Not reported                                                                                  Alive at 15 months follow-up with PSA 0.5 ng/mL/No data regarding rectal cancer

  Terris et al \[[@R13]\]     72                                             Not reported regarding rectal cancer/PSA 7.9 ng/mL                                                                                                                                                  Stage T2a, Gleason grade 3 + 4 prostate cancer          Not reported                                                                                           Preoperative radiotherapy + APR                                                                                              Not reported                                                                                  Alive at 10 months follow-up with PSA \< 0.5 ng/mL/No data regarding rectal cancer

  Terris et al \[[@R13]\]     73                                             Not reported regarding rectal cancer/PSA 32.4 ng/mL                                                                                                                                                 Stage T3, Gleason grade 4 + 4 prostate adenocarcinoma   Not reported                                                                                           Androgen deprivation therapy + APR                                                                                           Not reported                                                                                  Alive at 10 months follow-up with PSA 9 ng/mL/No data regarding rectal cancer

  Colonias et al \[[@R14]\]   58                                             Rectal bleeding-rectal mass at DRE, PSA 32 ng/mL                                                                                                                                                    stage II (T1cN0M0) prostate adenocarcinoma              stage III (T3N1M0), moderately differentiated rectal adenocarcinoma                                    Neoadjuvant CRT with androgen blockage, followed by proctosigmoidectomy and adjuvant chemotherapy with 5-FU and leucovorin   Not reported                                                                                  In 14-month follow-up asymptomatic with PSA 0.3 ng/mL
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: PSA: prostate specific antigen; DRE: digital rectal examination; APR: abdominoperineal resection; LAR: low anterior resection; LOS: length of stay.

Conclusions {#s4}
===========

Despite being an uncommon co-incidental finding, the existence of synchronous prostate and rectal cancer will be a clinical problem that will be encountered more frequently due to the increase in life expectancy, since they still remain two of the most frequent malignancies in the male population. Taking into consideration the complexity of a surgical intervention with a curative intent and the high likelihood to perform extended resections without being able to preserve the autonomic function, it is essential that careful preoperative planning and thorough discussion with the patients is performed, explaining the balance between optimal oncological surgery and preservation of the functional anatomy with better the quality of life with tissue sparing surgery. Moreover, the existence of multiple options in terms of neoadjuvant and adjuvant therapies may enable effective local control at least of one of the two primary tumors and sequentially be followed by a more oncologically feasible operation.
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